AZ-LIMELIGHT-NETWORKS
8.9.2020 16:28:09 CEST | Business Wire | Press release
Limelight Networks, Inc. (Nasdaq: LLNW ), a leading provider of content delivery network (CDN) and edge cloud services, has expanded its edge capabilities by launching EdgeFunctions, a new serverless compute service which allows developers to tap into the power of the company’s global network and gives them the flexibility to deploy and run their own code.
EdgeFunctions provides a customizable environment at the network edge for streamlining content workflows, performing time-sensitive decisions, and customizing user experiences. Providing this environment at the network edge offers Limelight’s low latency, on-demand scalability and high-performance network to developers. EdgeFunctions is ideal for streaming video and content delivery use cases such as personalized streaming, content protection, dynamic ad insertion, A/B testing, and image manipulation. Functions are globally available in Limelight’s highly distributed network and run closest to where content requests are received, ensuring Limelight’s lowest possible latency for code execution and optimal user experiences.
“We are thrilled to partner with Limelight to integrate our NexGuard Streaming forensic watermarking technology with EdgeFunctions and safeguard a premium OTT provider’s content from leaks and piracy,” said Jean-Philippe Plantevin, VP Anti-Piracy at NAGRA, a leading provider of content protection and multiscreen TV solutions. “Using EdgeFunctions, we were able to quickly deploy our customized solution into Limelight’s network edge locations and run them on demand, at scale, for both VOD and live OTT watermarking workflows.”
EdgeFunctions leverages Limelight’s global network to put flexibility and power directly into the hands of developers with support for several programming languages including Node.js, Python and Go. Its APIs enable these developers to manage, deploy and run their functions at the network edge and take advantage of Limelight’s direct peering connections with more than 1,000 ISPs and leading public cloud providers.
“Edge technology and solutions are rapidly expanding to meet a diverse set of customer needs. Limelight has an extensive global network with edge locations across the globe,” said Dave McCarthy, Research Director, Edge Strategies at IDC. “Giving developers more dynamic control over content combined with Limelight’s extensive global network optimizes the delivery of video at the edge.”
EdgeFunctions is Limelight’s latest innovation in the company’s edge compute solutions. These edge compute solutions now include serverless, virtual machine and bare metal solutions, providing edge compute capabilities how and where customers need them. In 2018 Limelight launched its first Edge Compute offering that allowed customers to access a highly connected environment that delivers low latency by combining globally distributed compute power with Limelight's high-performance network.
“We’ve evolved beyond high performing online video delivery with new innovative solutions to enhance online experiences and provide real value to our customers in ways that only we can. Now developers have the power to create and run bandwidth-intensive, latency-sensitive applications throughout our network edge,” said Bob Lento, CEO at Limelight. “Our extensive Edge Compute offering coupled with EdgeFunctions provides one of the most comprehensive content delivery and edge tool sets available today, and we have a robust development pipeline with much more to come. I’m thrilled to provide these services to the world’s leading companies.”
About Limelight
Limelight Networks, Inc. (NASDAQ: LLNW) is a global leader in delivering the highest quality online video experiences and edge-enabled workflows. Limelight has successfully helped launch and grow the largest video properties in the world and is on the forefront of enabling a new generation of applications that will disrupt markets and change our world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005739/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom